DEBRA GRAHAM: Open Payments
NPI 1790757623 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,994 in 90 payments from 11 companies in 2025. Trend: 2023 $344 · 2024 $953 · 2025 $1,994
Food & beverage: $1,900Education: $94
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 32 | $631 |
| Teva Pharmaceuticals USA, Inc. | 14 | $385 |
| Alkermes, Inc. | 15 | $244 |
| Vanda Pharmaceuticals Inc. | 8 | $231 |
| ABBVIE INC. | 5 | $114 |
| Otsuka America Pharmaceutical, Inc. | 5 | $112 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $97 |
| Lundbeck LLC | 3 | $72 |
| Axsome Therapeutics, Inc. | 3 | $53 |
| Janssen Pharmaceuticals, Inc | 1 | $35 |
Products named: INGREZZA, UZEDY, FANAPT, ARISTADA, REXULTI, VRAYLAR, CAPLYTA, Auvelity.
Industry payments across CA — which companies pay providers there.
